Background {#Sec1}
==========

Rates of colorectal cancer (CRC) in Australia are among the highest in the world \[[@CR1]\]. CRC is the second most commonly reported cancer in Australia, after prostate cancer and second most common cause of cancer death, after lung cancer, with approximately 16,000 new cases and 4000 deaths in 2012 \[[@CR2]\]. The cost of managing and treating CRC exceeds that for any other cancer, surpassing A\$427 million for 2008/09 \[[@CR3]\]. While survival from CRC is relatively favourable, outcomes are highly dependent on stage at diagnosis. Currently in Australia, five year relative survival is 86 % for localised CRC compared with 66 % for regional disease and only 12 % for distant spread \[[@CR4]\]. However, only one third of CRCs are 'localised' at diagnosis \[[@CR5]\]. Earlier detection of CRC should therefore lead to substantial improvements in survival \[[@CR6]\].

Reducing inequalities is an increasingly important focus of cancer control efforts, alongside improving survival overall. Socioeconomic and regional inequalities in survival from CRC have been observed internationally \[[@CR7]--[@CR16]\], and in Australia \[[@CR17]--[@CR19]\], despite many countries having universal healthcare. Reasons for sociodemographic differences in outcomes are not clear. Lower socioeconomic status (SES) is generally associated with later stage at diagnosis, and in some settings, poorer standards of care, less favourable health behaviours, and, or greater co-morbidity \[[@CR20], [@CR21]\]. Geographic variation may be due to lack of access to cancer screening and diagnostic services leading to later stage at diagnosis. Increased distance to cancer treatment services may deter or restrict patients from accessing or completing treatment, leading to disparities in treatment with consequent impacts on survival among rural patients \[[@CR22]--[@CR24]\]. Additionally limited follow-up facilities in remote locations may impact survival.

National data for Australia indicate disparities in CRC survival according to remoteness of residence and socioeconomic status at the area level \[[@CR3]\]. Five-year relative survival for remote residents was 62.8 % compared with 67.2 % for those living in major cities, and 64.5 % for those residing in the lowest SES quintile compared with 69.4 % in the highest SES quintile. Whether these disparities reflect differences in stage at diagnosis is unclear, due to the lack staging information in Australian cancer registries. Nor have any national or state-wide studies been undertaken covering both the public and private sector that include stage, comorbidity and treatment data to disentangle the impact of these factors on socioeconomic disparities.

This study aimed to identify factors associated with disparities in CRC survival using population-wide data from South Australia. Specifically we examined whether CRC survival differs according to area level measures of socioeconomic disadvantage and remoteness of residence. We also examined factors associated with stage at diagnosis, which may in part explain any survival differences we observe. We hypothesis that we should not see any disparities in survival according to area-level measures of disadvantage, after adjustment for stage, treatment and comorbidities, since healthcare is freely available to all Australian residents. On the other hand we would expect survival to vary according to place of residence, with poorer outcomes for more isolated residents due to limited access to healthcare services.

In Australia, healthcare services are generally delivered at the State level, along with administrative and surveillance data systems accompanying service delivery. Thus, population-based health services research is most feasible at the state level. While the population of South Australia is relatively small (1.5 million, approximately 8 % of Australia's total population), the geographic and socioeconomic variation across the state makes it an ideal population in which to explore disparities in CRC survival. Given the commonality in healthcare models across states, and the similarity with the nation-wide population profile, findings from South Australia will give insight into the nature of disparities at the national level. Further, they may confirm international findings suggesting socioeconomic and regional disparities in CRC survival despite universal healthcare.

Methods {#Sec2}
=======

Data sources and linkage {#Sec3}
------------------------

The study population comprised SA residents diagnosed with CRC (ICD10 C18-20) from January 2003 to December 2008, aged 50 and 79 years, identified from the South Australia Cancer Registry (SACR). This age range and diagnostic period corresponds to cases that were staged for a previous study on bowel cancer screening. Cases of squamous cell carcinoma, melanoma, carcinoid and baseloid tumours, perianal Paget's disease, gastrointestinal stromal tumours and cancers of unknown primary origin were excluded, since they are generally staged and managed quite differently. Synchronous colon and rectal cancer cases (*n* = 47) were classified together with rectal cancers.

A mixture of probabilistic and deterministic linkage methods were used to develop a comprehensive population-wide dataset incorporating demographic, clinical and outcome data for all CRC cases. SACR records pertaining to eligible cases constituted the core dataset. Linkage between the SACR and public hospital separation data was undertaken by SANT DataLink using probabilistic matching based on name, address and date of birth, to retrieve records pertaining to all admissions for each individual, which included an admission code for CRC. Linkage between the SACR and private hospital separation data, radiotherapy services and hospital-based cancer registries was undertaken by the Department of Health through direct matching of hospital codes, patient record numbers, cancer registry accession number and personal identifiers, again to identify all relevant records pertaining to CRC diagnosis or treatment from these data sources. SANT DataLink linkage processes followed the best practice principle of 'data separation' to ensure privacy and anonymity \[[@CR25]\]. Figure [1](#Fig1){ref-type="fig"} shows the data sources and linkage processes used in the construction of this dataset.Fig. 1Data sources and linkages used to compile study dataset

Measures {#Sec4}
--------

All eligible cases had previously been manually staged by SACR staff for a previous study \[[@CR5]\], according to Australian Clinico-Pathological Staging (ACPS) criteria \[[@CR26]\], based on data from pathology reports, supplemented by electronic patient records and hospital-based cancer registry (HBCR) data. Grade of the primary tumour at diagnosis was extracted from SACR records and was coded as low, intermediate or high grade corresponding to well-differentiated, moderately-differentiated and poorly-differentiated tumours based on pathological findings. Stage and grade were unknown in 278 (6.0 %) and 362 cases (7.8 %), respectively.

Area of residence was classified into 5 categories:- inner urban (very accessible), outer urban (moderately accessible), rural (accessible), remote and very remote, according to the Accessibility/Remoteness Index of Australia, 2006 \[[@CR27]\], based on residential postcode at diagnosis as recorded by the SACR. This measure describes place of residence according to road distance from population service centres. Remote and very remote categories were combined for analyses due to small numbers. Similarly, an area level measure of SES was assigned using the Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD) 2006 \[[@CR28]\], based on residential postcode. This index measures area-level rather than individual-level characteristics and represents the average socioeconomic status of specified neighbourhoods (in this case postal areas). It incorporates factors such as average household income, education levels and unemployment rates. SES was categorised into quintiles corresponding to SA\'s population distribution. No individual level measures of SES were available. Private health insurance status was assigned if any individuals' hospital admissions flagged the patient as being privately insured. Patient co-morbidity was assessed using the Charlson co-morbidity index (CCI) \[[@CR29]\] for the patient's first admission for surgical treatment or their first admission for CRC if there was no surgical admission. Diagnosis codes for CRC and metastatic disease were excluded when calculating the CCI. CCI scores were further categorised into no co-morbidity (CCI = 0), a single co-morbidity (CCI =1) or multiple co-morbidities (CCI \> =2).

Treatments were assessed from multiple sources and coded dichotomously (yes/no) based on any indication in any data source (i.e. any procedure codes for relevant treatment in hospital admissions, HBCR or radiotherapy records). 'Primary treatment' was defined as treatment commencing within 12 months of diagnosis, based on the date of the first hospital admission or the treatment start date in the HBCR or radiotherapy datasets if there was no hospital admission record for that treatment.

Information about vital status was derived from the SACR, which routinely links with state and national death notifications to track dates and causes of death occurring in any Australian jurisdiction.

Analysis {#Sec5}
--------

Ordinal logistic regression was undertaken to identify factors independently associated with stage at diagnosis. ACPS stage, categorised as four separate stages (A-D), was the dependent variable. Unknown stage was excluded. Adjusted odds ratios were obtained from a multivariate model adjusting for all covariates simultaneously (age group, sex, cancer site, SES (quintiles), place of residence, co-morbidity, primary surgery, radiotherapy, and chemotherapy, and calendar year of diagnosis (continuous). Cancer-specific survival was examined crudely, in the first instance, using Kaplan-Meier product limit estimates without taking competing risk into account, with differences assessed using log rank tests. We then assessed factors independently associated with risk of CRC death, using competing risk regression analysis according to the method of Fine and Gray \[[@CR30]\], where death from other causes was the competing risk. Cases were censored on December 31, 2012 or at their date of death (whichever occurred earlier). Follow-up time was calculated as the time from the date of diagnosis to the censoring date or date of death if death occurred before this date. Multivariable models included cancer site, stage, grade, age, sex, year of diagnosis, comorbidity categories, SES, place of residence, and primary treatments received. Cases with missing stage were excluded from analyses, whereas cases with missing grade were included as a separate 'unknown' category. We repeated the competing risk analysis with imputed data for missing stage and grade, derived using multiply imputed chained equations \[[@CR31]\], with 20 imputed data sets. Only complete case analyses are reported since results did not differ substantially for multiply imputed data. All analyses were undertaken using Stata v12.0 software \[[@CR32]\].

This study received ethical approval from Human Research Ethics Committees of SA Health, the Royal Adelaide Hospital, Flinders University/Medical Centre and the SA Aboriginal Health Council, along with data access approval from SA Health for government managed datasets.

Results {#Sec6}
=======

Dataset profile {#Sec7}
---------------

Of the 4949 CRC cases identified from the SACR, 113 were excluded due to ineligible histology, and 195 due to lack of hospital admission records, leaving a total of 4641 for analysis. The average period of follow-up was 4.7 yrs, corresponding to 6.3 yrs among survivors and 2.3 yrs among those who died of CRC or other causes. Demographic and clinical characters of the study cohort are presented in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the study population (CRC diagnosed among SA residents 50-79 yrs, 2003-2008)FactorTotal no. (%)TotalNumber (% of total)4641 (100)SexFemale1973 (42.5)Male2668 (57.5)Age50-59 yrs959 (20.7)60-69 yrs1601 (34.5)70-79 yrs2085 (44.8)Place ofInner urban3304 (71.2)residenceOuter urban459 (10.0)Rural621 (13.4)Remote257 (5.5)SocioeconomicLowest quintile1120 (24.1)statusMid-low939 (20.2)Mid849 (18.3)Mid-high897 (19.3)Highest quintile836 (18.0)Private InsuranceNo2082 (44.9)Yes2559 (55.1)Year2003789 (17.0)2004771 (16.6)2005722 (15.6)2006744 (16.0)2007828 (17.8)2008787 (17.0)Stage\#A933 (20.4)B1438 (30.1)C1345 (28.0)D649 (14.0)*unknown*278 (6.0)GradeLow123 (2.7)Intermediate3293 (71.0)High863 (18.6)*unknown*362 (7.8)Comorbidity^\*^None3236 (69.7)Single comorbidity819 (17.7)Severe or multiple586 (12.6)SiteColon3005 (64.7)Rectal or both1636 (35.3)\*Comorbidity assessed using Charlson comorbidity index\#ACPS -Australian clinico-pathological staging

Stage at diagnosis {#Sec8}
------------------

In unadjusted analyses, distribution of stage at diagnosis did not differ by remoteness of residence or SES, but did differ by cancer site, age group, extent of comorbidity and health insurance status (Table [2](#Tab2){ref-type="table"}). Multivariate analysis using ordinal logistic regression indicates that later stage was less likely among rectal cancer cases (0R = 0.81, 95 % CI 0.72-0.91), older patients (0R = 0.77, 95 % CI 0.67-0.89 for 70-79 yrs v 50-59 yrs) and privately insured patients (OR = 0.84, 95 % CI 0.75-0.95) and more likely for those with co-morbidities (OR = 1.50, 95 % CI 1.26-1.79 for CCI \> = 2 v 0). Stage at diagnosis was not associated with socioeconomic status (area-level), place of residence, or sex in multivariate analyses.Table 2Crude and adjusted odds ratios for factors associated with later stage at diagnosis derived from ordinal logistic regression (unknown stage excluded) *N* = 4362CrudeAdjusted\#VariablesOR95 % CI*p*-valueOR95 % CI*p*-valueSiteColon1.001.00Rectum0.820.73-0.91\<0.0010.810.72-0.91\<0.001Age group50-59 yrs1.001.0060-69 yrs0.820.70-0.95\<0.0080.760.66-0.89\<0.00170-79 yrs0.880.77-1.020.0870.770.67-0.890.001SexFemales1.001.00Males0.970.87-1.080.5620.960.86-1.070.436SESLowest (quintile)1.001.00Low0.890.75-1.060.2080.900.75-1.080.248Mid0.990.83-1.180.9090.960.79-1.150.636Low-high0.930.78-1.100.3950.900.75-1.080.268Highest1.080.91-1.260.4381.030.86-1.230.756ResidenceInner urban1.001.00Outer urban0.850.70-1.050.0800.890.74-1.070.248Rural1.020.88-1.200.7170.990.83-1.160.812Remote0.920.73-1.160.4730.990.77-1.260.912Private InsuranceNo1.001.00Yes0.880.76-0.940.0020.840.75-0.950.003Co-morbiditiesNone1.001.00One (not severe)1.251.09-1.440.0021.251.09-1.440.002Multiple or severe1.481.25-1.76\<0.0011.501.26-1.79\<0.001Diagnosis year2003-2008 (cont)0.970.94-1.000.0240.970.94-1.000.027\#Ordinal logistic regression model adjusted for all factors simultaneously -- excludes missing stage (*n* = 328)Ordinal logistic regression is an extension of logistic regression that incorporates the ordinal nature of the dependent variable (in this case stage at diagnosis). It can be used for modelling a dependant variable that has more than two ordered categories. The method is analogous to a series of binary models predicting the following combinations of binary stage groupings (e.g. stage A v stage B + C + D, A + B v C + D and A + B + C v D)

Survival outcomes {#Sec9}
-----------------

CRC specific survival was 88 %, 75 % and 69 % at 1, 3 and 5 years respectively (Table [3](#Tab3){ref-type="table"}). In crude analysis, survival was strongly associated with stage of disease, grade of tumour, age at diagnosis and severity of co-morbid conditions. Survival was also associated with receipt of specific treatments (with better survival among those having surgery compared with no surgery and worse survival for those who had radiotherapy or chemotherapy compared with those not receiving these treatments. There were no significant differences by place of residence but survival did differ across SES quintiles and according to whether patients were privately insured. Multivariate competing risk regression (Table [4](#Tab4){ref-type="table"}) revealed similar results, though there were some slight differences to crude survival analyses. Risk of CRC death was higher among patients with later stage disease (e.g. HR = 7.74, 95 % CI 5.75-10.4 for stage C vs stage A), higher grade (HR = 2.25, 95 % CI 1.32-3.84 for high verses low grade), and severe or multiple co-morbidities compared with no comorbidity (HR = 1.22, 95 % CI 1.02-1.44) and lower among rectal compared with colon cancer patients (HR = 0.85, 95 % CI 0.72-0.98). However there were no significant differences by age group or by health insurance status after adjusting for other covariates and accounting for death from other causes. Risk of CRC death was significantly lower among those who underwent surgery (HR = 0.51 95 % CI 0.42-0.62) and higher among those who received radiotherapy (HR = 1.41, 95 % CI 1.18-1.68), but unlike crude analyses, CRC death was lower among those who received chemotherapy (HR = 0.87 95 % CI 0.76-1.00). No differences were found according to place of residence, however risk was significantly lower among the highest compared with lowest SES group (HR = 0.75, 95 % CI 0.62-0.91). Risk of CRC death declined significantly over the study period (HR = 0.95, 95 % CI 0.92-0.98).Table 31, 3 and 5 year colorectal cancer cancer-specific survival \[%\], for South Australian residents aged 50-79 yr, diagnosed 2003-2008 (unadjusted). \[*N* = 8461\]CRC-survival (%)1 yr95 % CI3 yrs95 % CI5 yrs95 % CI*p*-value\#Total8887 - 897573 - 766968 - 71Age group50-59 yrs9189 - 927572 - 786865 - 7160-69 yrs9088 - 917674 - 797067 - 720.01670-79 yrs8584 - 877169 - 726664 - 68SexFemale8886 - 897472 - 766966 - 710.156Male8887 - 897472 - 756765 - 69Private InsuranceNo8583 - 867169 - 736562 - 67\<0.001Yes9189 - 927675 - 797068 - 72ResidenceInner urban8887 - 897572 - 766966 - 69Outer urban8784 - 907671 - 807166 - 750.219Rural8683 - 897469 - 766864 - 71Remote8983 - 927366 - 796456 - 70Very remote8467 - 927557 - 865938 - 76SES (quintiles)Least advantaged8684 - 887069 - 756461 - 67Mid-low8785 - 897471 - 776865 - 71Mid8785 - 897472 - 786966 - 720.010Mid-high8987 - 917472 - 786764 - 70Most advantaged9189 - 937875 - 817168 - 74ACP StageA9897 - 999795- 989593 - 96B9795 - 978987 - 908482 - 86C9189 - 927269 - 746259 - 64\<0.001D5450 - 581815 - 2197 - 12Unknown7266 - 775851 - 635649 - 62GradeLow9387 - 978779 - 928577 - 90Intermediate9392 - 948180 - 827573 - 76\<0.001High7774 - 795552 - 584946 - 53Unknown6661 - 714741 - 524337 - 48SiteColon8786 - 887372 - 746866 - 69Rectum9088 - 917673 - 786866 - 700.747Co-morbidityNone9089 - 917775 - 787069 - 72One (not severe)8785 - 897370 - 766864 - 71\<0.001Multiple / severe7571 - 785854 - 625248 - 56Surgery†No4641 - 512420 - 281916 - 24\<0.001Yes9291 - 937977 - 807371 - 74Radiotherapy†No8887 - 897574 - 767068 - 71\<0.001Yes8784 - 896763 - 715753 - 61Chemotherapy†No8887 - 898179 - 827775- 79\<0.001Yes8886 - 896259 - 645250 - 55\#Kaplan-meier log rank test†Treatments received within 12 months of diagnosisMean follow-up time to death or censoring of 40 months (sd = 24 months), median 36 months (inter-quartile range 21-59 months Table 4Multivariate competing risks regression analysis for risk of CRC death, all CRC patientsCRC death/ no. at riskAll CRC (n = 4365)HR95 % CI*p*-valueSiteColon923/28471.00\--Rectum487/15180.850.74-0.980.022Stage dukesA55/9331.00\--B250/14382.972.21-3.990.000C520/13457.745.75-10.40.000D585/64934.125.0-46.50.000GradeLow10/1141.00\--Intermediate826/31371.220.72-2.070.453High405/8252.251.32-3.840.003Unknown159/2892.091.20-3.640.010Age group50-59298/9011.00\--60-69467/15521.040.89-1.210.60070-79645/19421.120.96-1.290.146SexFemale585/18671.00\--Male825/24981.070.95-1.200.243Private InsuranceNo686/19851.00\--Yes724/23800.950.84-1.060.335ComorbidityNone941/30681.00\--One (not severe)248/7790.900.78-1.050.194Multiple / severe221/5181.211.02-1.440.033SES quintileLow382/10721.00\--Low-mid280/8780.940.80-1.110.443Middle246/7910.930.78-1.100.379Mid-high276/8431.060.90-1.250.508High226/7810.750.62-0.910.004ResidenceUrban1007/31021.00\--Outer urban122/4290.950.79-1.160.638Rural47/1880.980.82-1.170.830Remote93/2421.120.90-1.390.324Surgery^a^No230/2951.00\--Yes1180/40700.510.42-0.620.000Radiotherapy^a^No1141/37571.00\--Yes36/2691.411.18-1.680.000Chemotherapy^a^No632/27451.00\--Yes778/16200.870.76-1.000.047Diagnosis year(continuous)1410/43650.950.92-0.980.002CRC patients age 50-79 years diagnosed in South Australia 2003--3008Analysis with multiply imputed stage and grade, where missing, revealed similar results (i.e. identical patterns with regard to significant associations and approximately equivalent point estimates for all HRs)^a^Treatments received within 12 months of diagnosis

Results of stratified analyses, restricted to cases with potentially curable (stages A-C), or metastatic disease (stage D), are shown in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}. For potentially curable disease, risk of CRC death was higher among residents from remote regions compared with metropolitan residents (HR = 1.35, 95 % CI 1.01-1.80). Regional differences were not evident among patients with stage D CRC at diagnosis. Risk CRC death was lower among those in the highest compared with lowest socioeconomic quintile, both among those with potentially curable CRC (HR = 0.80, 95 % CI 0.63-1.01, non-significant) and for those with metastatic cancer (HR = 0.65, 95 % CI 0.47-0.89). Also private insurance was associated with improved outcomes (HR = 0.80, 95 % CI 0.67-0.96) among patients with metastatic disease at diagnosis but no difference was observed for those with stage A-C CRC. There was no evidence of improvement in survival for metastatic CRC patients over the study period, whereas there was a trend toward improved survival (reduced risk of death) over time for patients with stage A-C CRC (HR = 0.93, 95 % CI 0.90-0.97). Figure [2](#Fig2){ref-type="fig"} shows the cumulative mortality plots for CRC mortality, adjusted for covariates and competing risk of death from other causes by neighbourhood SES, for all cases, and place of residence for stage A-C CRC.Table 5Multivariate competing risks regression analysis for risk of death from CRC, for stages A-CCovariatesNo. CRC deaths/totalStages A-C (*n* = 3716)HR95 % CIp-valueSiteColon523/24091.00\--Rectum302/13070.940.78-1.140.538Stage dukesA55/9331.00\--B250/14382.932.18-3.940.000C520/13456.724.92-9.170.000GradeLow12/1041.00\--Intermediate512/27791.090.61-1.950.779High262/6702.131.18-3.870.013Unknown39/1631.590.82-3.070.172Age group50-59172/7581.00\--60-69282/13171.080.89-1.310.43370-79371/16411.120.93-1.360.240SexFemale348/16041.00\--Male477/21121.090.94-1.260.243Private InsuranceNo352/16251.00\--Yes473/20911.070.92-1.240.378ComorbidityNone580/26721.00\--One (not severe)142/6530.940.77-1.130.504Multiple / severe103/3911.291.02-1.620.032SES quintileLow216/8901.00\--Low-mid164/7490.980.79-1.200.819Middle142/6780.800.63-1.000.048Mid-high169/7301.000.80-1.240.967High134/6690.800.63-1.010.057ResidenceUrban578/26241.00\--Outer urban74/3740.960.74-1.230.724Rural117/5150.940.75-1.170.561Remote56/2031.351.01-1.800.040Surgery^a^No41/961.00\--Yes784/36200.380.26-0.560.000Radiotherapy^a^No656/32171.00\--Yes169/4991.481.16-1.880.002Chemotherapy^a^No399/24871.00\--Yes426/12291.110.92-1.350.284Diagnosis year(continuous)825/37160.930.90-0.970.002CRC patients age 50-79 years diagnosed in South Australia 2003--2008Analysis with multiply imputed stage and grade, where missing, revealed similar results (i.e. identical patterns with regard to significant associations and approximately equivalent point estimates for all HRs)^a^Treatments received within 12 months of diagnosis Table 6Multivariate competing risks regression analysis for risk of death from CRC, for stage D CRCCovariatesNo. CRC deaths/totalStage D (n = 649)HR95 % CIp-valueSiteColon400/4381.00\--Rectum185/2110.710.58-0.870.001Stage dukesA\-\--B\-\--C\-\--GradeLow8/101.00\--Intermediate314/3581.250.53-2.940.605High143/1552.040.86-4.830.105Unknown120/1262.260.94-5.420.067Age group50-59126/1431.00\--60-69185/2051.150.90-1.470.25470-79274/3011.150.90-1.460.261SexFemale237/2631.00\--Male348/3861.110.92-1.330.295Private InsuranceNo334/3601.00\--Yes251/2890.800.67-0.960.016ComorbidityNone361/3961.00\--One (not severe)106/1260.870.68-1.110.259Multiple / severe118/1271.130.87-1.450.364SES quintileLow166/1821.00\--Low-mid116/1290.850.65-1.110.231Middle104/1131.070.81-1.410.622Mid-high107/1131.150.90-1.480.259High92/1120.650.47-0.890.007ResidenceUrban429/4781.00\--Outer urban48/551.000.74-1.340.975Rural71/771.050.79-1.410.724Remote37/390.910.67-1.230.553Surgery^a^No189/1991.00\--Yes396/4500.580.46-0.720.000Radiotherapy^a^No485/5401.00\--Yes100/1091.250.98-1.580.068Chemotherapy^a^No233/2581.00\--Yes352/3910.620.51-1.040.000Diagnosis year(continuous)585/6490.990.94-1.040.619 Fig. 2Cumulative CRC mortality by **a** SES quintiles (for all cases 3 middle quintiles collapsed) and **b** remoteness of residence (cases with stages A-C at diagnosis) Fig. 2a and b represent cumulative incidence plots for CRC mortality by based on competing risk regression, for CRC cases diagnosed 2003-2008 among South Australians aged 50-79 yrs. Covariates include age, tumour site, stage, grade, co-morbidity, health insurance status, treatments received in first 12 months, and diagnosis year, categorised as described in methods. SES quintiles low-mid, mid, mid-high were collapsed into one category

Discussion {#Sec10}
==========

This study examined factors associated with disease-specific survival in a population-wide cohort of CRC patients with access to universal healthcare, with specific focus on identifying socioeconomic and regional disparities. As expected CRC survival was strongly associated with tumour characteristics at diagnosis (i.e. poorer outcomes for more advanced stage and higher grade). However we also found evidence of area level socioeconomic and regional differences in survival for certain subgroups of patients, after accounting for clinical factors including stage. Outcomes were significantly better for those living in the highest compared with lowest SES neighbourhoods, with a more pronounced effect for metastatic disease. We also observed better outcomes among privately insured patients with metastatic disease. Significantly worse outcomes were observed among those living in remote compared with metropolitan regions, though this applied to potentially curable disease only.

While our results suggest that CRC survival differs according to SES, despite provision of universal healthcare services, some observations weaken this conclusion. There was no clear 'dose response' with increasing SES. Among stage A-C cases, risk differences for the highest compared with lowest SES areas did not reach statistical significance when restricted to those with stage A-C disease. Furthermore, our measure of SES was based on characteristics of an individual's neighbourhood, rather than individual measures such as the person's education, occupation or income level. Thus, there is potential for misclassification of SES at the individual level, which may have led to inaccurate findings.

The existing body of international literature showing socioeconomic inequalities in CRC survival, across numerous countries with differing health care systems \[[@CR7]--[@CR12]\], supports our findings. Many of these studies show that disparities persist after adjustment for differences in stage \[[@CR20]\]. Evidence from Australian-based studies is mixed. Hall et al. (Western Australia) \[[@CR33]\] and Jorgensen et al. (New South Wales) \[[@CR34]\] found no association between SES and CRC outcomes, while Kelsall et al. (Victoria) \[[@CR35]\], Morris et al. (Western Australia) \[[@CR36]\] and Baade et al. (Queensland) \[[@CR18]\] did observed socioeconomic disparities. All used area-level measures of SES compiled by the ABS. Our findings provide further evidence of inequalities in CRC according to area-level deprivation in Australia, despite universal access to health care, with similar effect sizes to previous Australian studies (\~25 % difference for highest to lowest SES groups) but slightly lower than international estimates \[[@CR20]\].

Various explanations for socioeconomic disparities in CRC survival include differences in screening patterns, distribution of stage of disease, lifestyle factors, co-morbidities, access to health care services and inequalities in treatments. In their review, Aarts et al. note the difficulty in attributing SES differences in survival to any one specific factor \[[@CR20]\]. Likewise, Palmer and Schneider highlight socioeconomic disparities across the spectrum of colorectal cancer control including early detection, diagnosis, treatment and outcomes, and call for a multidisciplinary approach to tackling inequalities \[[@CR21]\]. Since we found no evidence of differences in stage distribution according to SES, it is unlikely that disparities are due to more advanced disease stage in areas with low SES. Furthermore we adjusted for stage in our regression models. While we also adjusted for co-morbidities using the Charlson co-morbidity index, we were unable to adjust for general lifestyle factors such as obesity, tobacco use, lack of physical activity, due to the lack of individual level data, so cannot rule out the influence of these factors. Our previous research found no overall difference in compliance with treatment guidelines, though radiotherapy for rectal cancer was less likely among more advantaged groups \[[@CR37]\]. No differences were observed for surgery or chemotherapy by SES. Differences in treatment (at the broad level) do not explain survival patterns in the current study. Furthermore, inclusion of treatments in regression models did not attenuate the observed associations with survival outcomes. However, other treatment related factors like continuation of chemotherapy, resection of liver metastases and access to follow-up care may vary by SES. Further investigation is warranted to determine the mediating pathways for these disparities.

Our study also found poorer outcomes for those from remote locations for stage A to C disease. Regional disparities were not observed for metastatic (stage D) disease, which is consistent with previous finding from clinical registry data \[[@CR38]\]. Some caution in our interpretation is warranted given we did not observed any significant differences in the whole study population. Distance from treatment facilities has previously been shown to impact CRC survival in Australia \[[@CR17], [@CR18]\], and internationally \[[@CR13]--[@CR16]\]. Baade et al. \[[@CR17]\], found that risk of mortality from rectal cancer increased by 6 % with every 100 km distance from a radiotherapy centre for rectal patients in Queensland (Australia). In a subsequent study the same authors also found that CRC patients residing in remote locations had 14 % lower 5 yr-survival compared with their urban counterparts \[[@CR18]\]. Similar to our finding, they noted disparities only in relation to residents from remote locations. They hypothesise that regional differences may be due to patient factors (lifestyle factors and co-morbidities) as well as management patterns, and clinical experience in regional hospitals. We were unable to identify any obvious pathway through which regional disparities in survival could be explained. Poorer survival among patients from remote areas with stage A-C CRC suggest inequalities in access to, or quality of, care rather than regional differences in stage at diagnosis. Findings from our previous patterns of care study (in the same cohort) indicated that rural and remote patients with stage C colon cancer were less likely to receive chemotherapy \[[@CR37]\], which may be one reason for poorer outcomes. Differences in follow-up care after initial treatment by place of residence may be another explanation. Again further research to address the causes of poorer survival among potentially curable patients from more remote areas is required.

We also observed differences in survival according to treatment modalities. Patients who underwent surgery or received chemotherapy (for Stage D disease) had better survival while patients who recieved radiotherapy had poorer outcomes than those not receiving these treatments. Reasons for better outcomes with surgery are likely to relate to patients' fitness for surgery or inoperability of the tumour. Likewise receipt of chemotherapy is less likely among frail or unfit patients, who are also likely to have poorer survival outcomes. Thus the results would be consistent with decisions not to offer chemotherapy when there is likely to be limited effectiveness, high risk of side effects, or both. Poorer cancer specific survival among radiotherapy recipients may be due to radiotherapy being given with palliative rather than curative intent in some cases.

Strengths and limitations {#Sec11}
-------------------------

This study demonstrates the utility of record linkage, using administrative and health surveillance databases, to evaluate disparities in outcomes for cancer patients. Record linkage offers considerable advantages over institutionally-based studies when examining disparities according to socioeconomic status or place of residence \[[@CR39]\]. The inclusion of all eligible patients, regardless of whether they attended public or private health care services or both, greatly reduces the potential for selection bias to have influenced our results.

Our findings in relation to SES are based on area-level rather than individual level measures of SES, so may not accurately measure the level of socioeconomic disadvantage for individuals. Ideally, individual measures such as income, education level, housing and car ownership would be preferable, however these data are hard to obtain at a population level. Area level measures of neighbourhood deprivation are commonly used to identify socioeconomic disparities at the population-wide level. IRSAD is a rigorously constructed, composite measure of socioeconomic advantage and disadvantage based on census data for small areas which has been widely used to assess SES disparities in Australia \[[@CR40]\]. Previous data linkage studies have been hampered by lack of staging data or incomplete information on treatments, particularly those provided through the private health sector. While we made use of staging data from a previous research project, cancer registries across Australia do not routinely collect stage. High priority needs to be given to developing sustainable systems to collect and record staging information within central cancer registries to enhance their value and usefulness in health outcomes research. Cancer Australia initiatives to pilot the collection of staging information in Australian cancer registries are promising developments \[[@CR41]\].

Concerns are often raised about the quality and consistency of administrative data, particularly in relation to treatments and comorbidity \[[@CR42]\]. Linkage across multiple data sources including hospital admission records, clinical registries and public and private radiotherapy services enhanced our ability to capture broad level treatment information. Our study would have been further enhanced had we had access to national pharmaceutical prescription data, through linkage with the national database, to better ascertainment of chemotherapy administered in outpatient and community settings \[[@CR43]\]. The establishment of data integrating authorities, which is underway throughout Australia, will provide greater access to such data which are crucial for evaluating effectiveness of cancer care \[[@CR44]\]. While we acknowledge the limitations of using administrative data sources to determine treatment information, undertaking case note reviews at a population level would be impractical and the cost prohibitive. Linkage derived measures are likely to be sufficient for epidemiological studies, though further research is warranted to valid measures and determine the impact of inaccuracies on population-based research.

Conclusion {#Sec12}
==========

This study points to disparities in CRC survival in South Australia according to socioeconomic characteristics and remoteness of patients' place of residence, despite universal access to healthcare. The reasons for these disparities remain unclear, but do not appear to be due to differences in stage or other prognostic factors, age, comorbid disease burden or treatment difference at a broad level, though access to chemotherapy may be a contributing factor. Our analyses were unable to account for individual lifestyle risks, treatment differences at a more detailed level, hospital/clinician volume or access to follow-up care, some or all of which may be contributing to these disparities. Further research is required to identify the underlying causes of these disparities which can be addressed to achieve equitable outcomes for all patients irrespective of social position or place of residence.
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